MiMedx Group, Inc (MDXG): Price and Financial Metrics
GET POWR RATINGS... FREE!
MDXG POWR Grades
- Sentiment is the dimension where MDXG ranks best; there it ranks ahead of 96.69% of US stocks.
- The strongest trend for MDXG is in Growth, which has been heading up over the past 179 days.
- MDXG ranks lowest in Momentum; there it ranks in the 13th percentile.
MDXG Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for MDXG is -14.89 -- better than merely 1.28% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at -11.74 for MIMEDX GROUP INC; that's greater than it is for only 1.81% of US stocks.
- Over the past twelve months, MDXG has reported earnings growth of 181.89%, putting it ahead of 91.82% of US stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to MIMEDX GROUP INC are SIEN, DTSS, TZOO, ESTA, and MKTW.
- Visit MDXG's SEC page to see the company's official filings. To visit the company's web site, go to www.mimedx.com.
MDXG Valuation Summary
- MDXG's EV/EBIT ratio is -12.8; this is 295.42% lower than that of the median Healthcare stock.
- Over the past 184 months, MDXG's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for MDXG.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| MDXG | 2023-03-17 | 1.6 | -23.4 | -11.4 | -12.8 |
| MDXG | 2023-03-16 | 1.6 | -23.5 | -11.5 | -12.9 |
| MDXG | 2023-03-15 | 1.5 | -22.6 | -11.0 | -12.3 |
| MDXG | 2023-03-14 | 1.6 | -23.8 | -11.6 | -13.0 |
| MDXG | 2023-03-13 | 1.6 | -24.5 | -12.0 | -13.4 |
| MDXG | 2023-03-10 | 1.6 | -24.4 | -11.9 | -13.4 |
MDXG Growth Metrics
- The 3 year price growth rate now stands at -24.26%.
- The 2 year price growth rate now stands at -24.26%.
- The year over year net cashflow from operations growth rate now stands at 77.59%.
The table below shows MDXG's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-12-31 | 267.841 | -17.893 | -36.777 |
| 2022-09-30 | 260.875 | -15.501 | -34.049 |
| 2022-06-30 | 256.26 | -10.13 | -27.866 |
| 2022-03-31 | 257.542 | -5.526 | -18.646 |
| 2021-12-31 | 258.615 | -1.982 | -16.421 |
| 2021-09-30 | 259.754 | -9.017 | -35.098 |
MDXG's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- MDXG has a Quality Grade of C, ranking ahead of 64.26% of graded US stocks.
- MDXG's asset turnover comes in at 1.366 -- ranking 8th of 186 Medical Equipment stocks.
- 500 - Internal server error
The table below shows MDXG's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 1.366 | 0.833 | -0.426 |
| 2021-06-30 | 1.316 | 0.833 | -1.110 |
| 2021-03-31 | 1.302 | 0.842 | -1.153 |
| 2020-12-31 | 1.369 | 0.842 | -1.200 |
| 2017-09-30 | 1.597 | 0.881 | 0.532 |
| 2017-06-30 | 1.485 | 0.878 | 0.420 |
MDXG Price Target
For more insight on analysts targets of MDXG, see our MDXG price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $16.17 | Average Broker Recommendation | 1.5 (Moderate Buy) |
MDXG Stock Price Chart Interactive Chart >
MDXG Price/Volume Stats
| Current price | $3.54 | 52-week high | $5.05 |
| Prev. close | $3.44 | 52-week low | $2.43 |
| Day low | $3.46 | Volume | 621,600 |
| Day high | $3.61 | Avg. volume | 580,493 |
| 50-day MA | $4.02 | Dividend yield | N/A |
| 200-day MA | $3.48 | Market Cap | 403.85M |
MiMedx Group, Inc (MDXG) Company Bio
MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue.
Latest MDXG News From Around the Web
Below are the latest news stories about MIMEDX GROUP INC that investors may wish to consider to help them evaluate MDXG as an investment opportunity.
MIMEDX Announces Chief Financial Officer TransitionExecutive Search UnderwayMARIETTA, Ga., March 23, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that Peter M. Carlson, Chief Financial Officer, has decided to leave the Company to pursue other opportunities. The Company has initiated a search for its next Chief Financial Officer and Mr. Carlson will be assisting MIMEDX throughout this process to ensure a smooth transition. “In the three years P |
MIMEDX Comments on Recent Data Brief Published by Office of Inspector GeneralCompany applauds the Office of Inspector General’s (“OIG”) recommendation for the Centers for Medicare and Medicaid Services (“CMS”) to quickly address issues associated with Average Sales Price (“ASP”) reporting requirements for skin substitute productsMARIETTA, Ga., March 16, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today applauded the recent report published by OIG entitled, “Some Skin Substitute Manuf |
MiMedx Group, Inc. (NASDAQ:MDXG) Q4 2022 Earnings Call TranscriptMiMedx Group, Inc. (NASDAQ:MDXG) Q4 2022 Earnings Call Transcript February 28, 2023 Operator: Good afternoon, and thank you for standing by. Welcome to the MiMedx Fourth Quarter and Full Year 2022 Operating and Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. […] |
MiMedx Group Full Year 2022 Earnings: In Line With ExpectationsMiMedx Group ( NASDAQ:MDXG ) Full Year 2022 Results Key Financial Results Revenue: US$267.8m (up 3.6% from FY 2021... |
Institutional investors own a significant stake of 38% in MiMedx Group, Inc. (NASDAQ:MDXG)Key Insights Institutions' substantial holdings in MiMedx Group implies that they have significant influence over the... |
MDXG Price Returns
| 1-mo | -22.03% |
| 3-mo | 27.80% |
| 6-mo | 29.20% |
| 1-year | -25.00% |
| 3-year | 123.34% |
| 5-year | 5.83% |
| YTD | 27.34% |
| 2022 | -53.97% |
| 2021 | 33.04% |
| 2020 | 19.79% |
| 2019 | 323.46% |
| 2018 | -85.80% |
Loading social stream, please wait...